SLN
Silence Therapeutics plc
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Neutral
+13/100
Last price
9.82
▼ 0.01 (0.10%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
9.77
Prev close
9.83
Day high
10.14
Day low
9.60
Volume
1.32M
Market cap
$610.35M
P/E (TTM)
—
52W range
4.19 – 17.58
Day trading desk
Gap from prior close
-3.65%
Prior close 10.14
VWAP
9.95
-1.29% from price
Relative volume
1.19×
Normal
Session range
5.62%
9.60 – 10.14
Position in range
41%
Mid range
ATR (14D)
0.55
5.65% of price
Prior day high
10.65
PDH
Prior day low
10.05
PDL
Bid / ask spread
—
Quote not published
Session volume
1.31M
Avg 1.11M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-8.98%
-10.9%
1M
-32.63%
-33.8%
3M
-1.21%
-5.7%
6M
+75.54%
+57.4%
YTD
+61.68%
+47.4%
1Y
+96.60%
+80.2%
3Y
+0.10%
-82.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on SLN open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
3.76M
Total on file
Fundamentals
Market cap$610.35M
Enterprise value$392.02M
Revenue (TTM)$615.00K
Gross profit$528.00K
EBITDA$-63.94M
Net income$-59.95M
EPS (TTM)$-1.29
Free cash flow$-23.57M
Total cash$72.05M
Total debt$112.00K
Book value / share$0.81
Shares outstanding62.15M
Float37.85M
Short % of float4.30%
Dividend yield0.00%
Beta (5Y)1.45
Valuation & profitability ratios
Trailing P/E—
Forward P/E-25.84
PEG ratio—
Price / sales—
Price / book12.06
EV / revenue637.43
EV / EBITDA-6.13
Gross margin85.85%
Operating margin-10475.61%
Profit margin0.00%
Return on equity-90.41%
Return on assets-29.65%
Debt / equity0.29
Current ratio7.42
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $559.00K | $43.26M | $31.64M | $21.66M | -98.7% |
| Operating revenue | $559.00K | $43.26M | $31.64M | $21.66M | -98.7% |
| Cost of revenue | $215.00K | $11.81M | $12.87M | $13.46M | -98.2% |
| Gross profit | $344.00K | $31.45M | $18.78M | $8.19M | -98.9% |
| Research & development | $67.75M | $67.88M | $56.94M | $43.55M | -0.2% |
| Selling, general & admin | $22.34M | $26.88M | $26.22M | $25.68M | -16.9% |
| Total operating expense | $90.10M | $94.77M | $83.16M | $69.23M | -4.9% |
| Operating income | -$89.75M | -$63.32M | -$64.38M | -$61.04M | -41.7% |
| Net interest income | $3.48M | $4.47M | $1.80M | $280.00K | -22.2% |
| Pre-tax income | -$88.60M | -$44.46M | -$53.27M | -$49.65M | -99.3% |
| Tax provision | $11.00K | $845.00K | $956.00K | $688.00K | -98.7% |
| Net income | -$88.61M | -$45.31M | -$54.23M | -$50.33M | -95.6% |
| Net income to common | -$88.61M | -$45.31M | -$54.23M | -$50.33M | -95.6% |
| Basic EPS | -1.89 | -0.99 | -1.47 | -1.56 | -90.9% |
| Diluted EPS | -1.89 | -0.99 | -1.47 | -1.56 | -90.9% |
| EBIT | -$89.75M | -$63.32M | -$64.38M | -$61.04M | -41.7% |
| EBITDA | -$89.20M | -$62.73M | -$63.76M | -$60.44M | -42.2% |
| Basic shares | 47.23M | 46.25M | 37.09M | 32.19M | +2.1% |
| Diluted shares | 47.23M | 46.25M | 37.09M | 32.19M | +2.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $11.28M | $121.33M | $68.79M | $66.34M | -90.7% |
| Cash & short-term investments | $85.11M | $147.33M | $68.79M | $86.10M | -42.2% |
| Accounts receivable | $0 | $972.00K | $290.00K | $1.11M | -100.0% |
| Total current assets | $118.66M | $187.37M | $103.15M | $117.01M | -36.7% |
| Property, plant & equipment | $1.75M | $2.33M | $2.67M | $2.66M | -25.0% |
| Goodwill & intangibles | $10.91M | $9.70M | $10.34M | $10.08M | +12.4% |
| Total assets | $131.44M | $202.63M | $119.45M | $130.10M | -35.1% |
| Total current liabilities | $13.61M | $16.82M | $22.34M | $26.56M | -19.1% |
| Total debt | $160.00K | $117.00K | $346.00K | $539.75K | +36.8% |
| Total liabilities | $69.14M | $68.61M | $97.45M | $103.38M | +0.8% |
| Retained earnings | -$562.57M | -$474.04M | -$431.89M | -$318.60M | -18.7% |
| Shareholder equity | $62.30M | $134.02M | $21.99M | $26.71M | -53.5% |
| Working capital | $105.05M | $170.54M | $80.81M | $90.45M | -38.4% |
| Net tangible assets | $51.40M | $124.32M | $11.65M | $16.63M | -58.7% |
| Shares issued | 141.70M | 141.67M | 118.85M | 107.81M | +0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$88.61M | -$45.31M | -$54.23M | -$50.33M | -95.6% |
| Depreciation & amortisation | $555.00K | $593.00K | $621.00K | $596.00K | -6.4% |
| Stock-based compensation | $8.07M | $16.31M | $16.27M | $12.69M | -50.5% |
| Change in working capital | $10.16M | -$33.02M | -$15.24M | -$19.40M | +130.8% |
| Operating cash flow | -$62.27M | -$67.64M | -$49.46M | -$57.04M | +7.9% |
| Capital expenditure | -$55.00K | -$211.00K | -$56.00K | -$545.00K | +73.9% |
| Investing cash flow | -$47.99M | -$21.97M | $19.29M | -$20.50M | -118.5% |
| Financing cash flow | $15.00K | $142.09M | $31.94M | $52.58M | -100.0% |
| Free cash flow | -$62.33M | -$67.85M | -$49.52M | -$57.59M | +8.1% |
| End cash position | $11.28M | $121.33M | $68.79M | $66.27M | -90.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $422.00K | $34.00K | $159.00K | $224.00K | — | -100.0% |
| Operating revenue | $0 | $422.00K | $34.00K | $159.00K | $224.00K | — | -100.0% |
| Cost of revenue | $0 | $11.00K | $12.00K | $64.00K | $85.00K | — | -100.0% |
| Gross profit | $0 | $411.00K | $22.00K | $95.00K | $139.00K | — | -100.0% |
| Research & development | $9.15M | $9.12M | $8.75M | $20.54M | $17.65M | — | +0.3% |
| Selling, general & admin | $4.72M | $7.03M | $3.73M | $5.79M | $5.13M | — | -32.9% |
| Total operating expense | $13.87M | $16.15M | $12.48M | $26.34M | $22.78M | — | -14.1% |
| Operating income | -$13.87M | -$15.74M | -$12.46M | -$26.24M | -$22.64M | — | +11.9% |
| Pre-tax income | -$12.27M | -$14.96M | -$11.77M | -$20.96M | -$27.34M | — | +18.0% |
| Tax provision | $1.00K | $0 | $0 | $1.00K | $10.00K | — | — |
| Net income | -$12.27M | -$14.96M | -$11.77M | -$20.96M | -$27.35M | — | +18.0% |
| Net income to common | -$12.27M | -$14.96M | -$11.77M | -$20.96M | -$27.35M | — | +18.0% |
| Basic EPS | -0.27 | -0.33 | — | -0.45 | -0.57 | -0.60 | +18.2% |
| Diluted EPS | -0.27 | -0.33 | — | -0.45 | -0.57 | -0.60 | +18.2% |
| EBIT | -$13.87M | -$15.74M | -$12.46M | -$26.24M | -$22.64M | — | +11.9% |
| EBITDA | -$13.76M | -$15.63M | -$12.35M | -$26.09M | -$22.49M | — | +12.0% |
| Basic shares | 47.24M | 47.23M | — | 47.23M | 47.23M | 47.23M | +0.0% |
| Diluted shares | 47.24M | 47.23M | — | 47.23M | 47.23M | 47.23M | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $72.05M | $5.66M | $11.28M | $82.03M | $41.74M | — | +1,173.7% |
| Cash & short-term investments | $72.05M | $70.08M | $85.11M | $102.19M | $114.16M | — | +2.8% |
| Accounts receivable | — | $0 | $0 | $28.00K | $85.00K | $41.00K | — |
| Total current assets | $94.28M | $102.85M | $118.66M | $133.63M | $148.55M | — | -8.3% |
| Property, plant & equipment | $1.44M | $1.54M | $1.75M | $1.85M | $1.83M | — | -6.2% |
| Goodwill & intangibles | $10.56M | $10.61M | $10.91M | $10.91M | $10.93M | — | -0.4% |
| Total assets | $106.41M | $115.12M | $131.44M | $146.79M | $165.23M | — | -7.6% |
| Total current liabilities | $12.71M | $10.46M | $13.61M | $17.38M | $14.77M | — | +21.5% |
| Total debt | $112.00K | $136.00K | $160.00K | $182.00K | $0 | — | -17.6% |
| Total liabilities | $67.94M | $65.72M | $69.14M | $72.73M | $71.08M | — | +3.4% |
| Retained earnings | -$589.63M | -$577.53M | -$562.57M | -$550.80M | -$529.84M | — | -2.1% |
| Shareholder equity | $38.47M | $49.40M | $62.30M | $74.06M | $94.16M | — | -22.1% |
| Working capital | $81.57M | $92.39M | $105.05M | $116.25M | $133.78M | — | -11.7% |
| Net tangible assets | $27.91M | $38.80M | $51.40M | $63.15M | $83.22M | — | -28.1% |
| Shares issued | 141.74M | 141.70M | 141.70M | 141.70M | 141.70M | — | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$12.27M | -$14.96M | -$11.77M | -$20.96M | -$27.35M | — | +18.0% |
| Depreciation & amortisation | $108.00K | $106.00K | $113.00K | $156.00K | $148.00K | — | +1.9% |
| Stock-based compensation | $1.31M | $2.45M | -$86.00K | $2.54M | $2.08M | — | -46.5% |
| Change in working capital | $12.78M | -$2.65M | -$4.89M | $9.06M | -$4.50M | — | +581.2% |
| Operating cash flow | $1.52M | -$15.60M | -$17.29M | -$10.89M | -$21.78M | — | +109.7% |
| Capital expenditure | — | — | — | -$3.00K | -$48.00K | -$4.00K | — |
| Investing cash flow | $64.94M | $10.00M | -$53.34M | $51.29M | -$1.56M | — | +549.4% |
| Financing cash flow | $2.00K | $0 | $0 | $0 | $1.00K | — | — |
| Free cash flow | $1.52M | -$15.60M | -$17.29M | -$10.89M | -$21.83M | — | +109.7% |
| End cash position | $72.05M | $5.66M | $11.28M | $82.03M | $41.74M | — | +1,173.7% |
Options analytics
Put / call volume
0.07
Call-heavy session
Put / call open interest
0.06
Positioning, not flow
Max pain
5.00
-49.1% from spot
ATM implied vol
151.2%
Nearest strike to spot
Skew (10% OTM)
-69.9%
Calls bid over puts
Call volume
2.19K
Contracts, this expiry
Put volume
162
Contracts, this expiry
Heaviest call OI
15.00
7.92K contracts
Heaviest put OI
12.50
1.31K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.11 | -0.27 | -145.5% |
| Mar 2026 | -0.09 | -0.33 | -266.7% |
| Dec 2025 | -0.49 | -0.27 | +44.9% |
| Sep 2025 | -0.21 | -0.15 | +27.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.09 | 1 | $20.67K | -83.0% |
| Next quarter | -0.10 | 1 | $4.50K | -82.3% |
| Current year | -0.37 | 2 | $322.44K | -22.9% |
| Next year | -0.38 | 2 | $750.53K | +132.8% |
Analyst targets & ownership
Mean target$33.00
High target$75.00
Low target$10.00
Implied upside236.05%
Analyst count6
ConsensusBUY
Strong buy / Buy1 / 5
Hold0
Sell / Strong sell1 / 0
Held by insiders7.97%
Held by institutions44.36%
Institutions holding91
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
10.82
-9.21% from price
SMA 20
11.78
-16.52% from price
SMA 50
12.62
-22.09% from price
SMA 100
10.49
-6.35% from price
SMA 200
8.24
+19.28% from price
EMA 12
11.01
-10.82% from price
EMA 26
11.76
-16.47% from price
EMA 50
11.80
-16.81% from price
RSI (14)
23.9
Oversold
MACD (12,26,9)
-0.74
Hist -0.22
ATR (14)
0.55
5.64% of price
Realised vol 30D
45.6%
Annualised
Bollinger upper
13.91
20, 2σ
Bollinger lower
9.64
20, 2σ
50 / 200 cross
Golden
12.62 vs 8.24
Trend bias
Above 200
+19.28%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.45
More volatile than market
Correlation to SPY
0.22
Largely independent
Realised vol 30D
45.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-41.9%
Peak to trough
Max drawdown 5Y
-91.7%
Peak to trough
ATR 14
0.55
5.64% of price
Beta (reported)
1.45
5Y monthly, from filing
Short interest
Shares short
2.18M
Prior 2.43M
Change vs prior
-10.5%
Shorts covering
% of float
4.30%
Normal
% of shares out
3.50%
Against total outstanding
Days to cover
2.8
Liquid
Float
37.85M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 11, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Jun 24, 26 | Cantor Fitzgerald | INITIATED | — | Overweight |
| Jun 17, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 13, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 16, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 8, 25 | Chardan Capital | MAINTAINED | Buy | Buy |
| Jun 13, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 13, 25 | Chardan Capital | MAINTAINED | Buy | Buy |
| May 9, 25 | Goldman Sachs | MAINTAINED | Sell | Sell |
| May 9, 25 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| May 9, 25 | Chardan Capital | MAINTAINED | Buy | Buy |
| Mar 7, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Offering Registrations
S-3MEF · 2026-08-11
Corporate Changes & Voting Matters
8-K · 2026-08-10
Corporate Changes & Voting Matters
8-K/A · 2026-07-16
Corporate Changes & Voting Matters
8-K · 2026-06-23
Corporate Changes & Voting Matters
8-K · 2026-06-16
Corporate Changes & Voting Matters
8-K · 2026-06-11
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-05-22
Offering Registrations
S-3 · 2026-05-18
Headlines
Silence Therapeutics to Participate in Three September Investor Conferences
Business Wire · 36d ago
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs
Business Wire · 54d ago
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
Business Wire · 57d ago
Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial
MarketBeat · 58d ago
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares
Business Wire · 58d ago
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
Business Wire · 59d ago
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
Business Wire · 59d ago
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
Business Wire · 59d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.